Compare VNT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNT | BLCO |
|---|---|---|
| Founded | 2019 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.9B |
| IPO Year | 2020 | 2022 |
| Metric | VNT | BLCO |
|---|---|---|
| Price | $29.21 | $15.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $46.89 | $18.45 |
| AVG Volume (30 Days) | ★ 2.0M | 412.2K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ 0.36 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | $3,075,600,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $2.39 | $8.65 |
| Revenue Next Year | $4.19 | $5.59 |
| P/E Ratio | $43.44 | ★ N/A |
| Revenue Growth | 3.24 | ★ 6.47 |
| 52 Week Low | $27.25 | $11.44 |
| 52 Week High | $48.20 | $18.92 |
| Indicator | VNT | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 40.13 |
| Support Level | $27.47 | $14.55 |
| Resistance Level | $29.74 | $15.57 |
| Average True Range (ATR) | 0.78 | 0.38 |
| MACD | 0.31 | -0.02 |
| Stochastic Oscillator | 74.63 | 24.58 |
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3.1 billion in sales in 2025.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.